Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Beam Therapeutics Inc. BEAM NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
53/100
3/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$40.86
+34.9%

Beam Therapeutics Inc. (BEAM) is a Biotechnology company in the Healthcare sector, currently trading at $30.30. It has a SharesGrow Score of 53/100, indicating a mixed investment profile with 3 out of 7 criteria passed.

Analyst consensus target is BEAM = $41 (+34.9% upside).

Valuation: BEAM trades at a trailing Price-to-Earnings (P/E) of -33.5 (S&P 500 average ~25).

Financials: revenue is $140M, +185.6%/yr average growth. Net income is $80M (loss), growing at -18.6%/yr. Net profit margin is -57.2% (negative). Gross margin is 84% (+21.1 pp trend).

Balance sheet: total debt is $294M against $1.2B equity (Debt-to-Equity (D/E) ratio 0.24, conservative). Current ratio is 13.09 (strong liquidity). Debt-to-assets is 19.8%. Total assets: $1.5B.

Analyst outlook: 18 / 27 analysts rate BEAM as buy (67%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 90/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 67/100 (Partial), Moat 70/100 (Pass), Future 73/100 (Pass), Income 10/100 (Fail).

$40.86
▲ 34.85% Upside
Average Price Target
Based on 27 Wall Street analysts offering 12-month price targets for Beam Therapeutics Inc., the average price target is $40.86, with a high forecast of $74.00, and a low forecast of $26.00.
Highest Price Target
$74.00
Average Price Target
$40.86
Lowest Price Target
$26.00

BEAM SharesGrow Score Overview

61/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 90/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 70/100
Gross margin is + market cap
FUTURE 73/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — BEAM

✓
VALUE Pass
90/100
BEAM trades at a trailing Price-to-Earnings (P/E) of -33.5 (S&P 500 average ~25). Forward PEG -11.29 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $41, implying +35.3% from the current price $30. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
58/100
BEAM: +185.6%/yr revenue is, -18.6%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet BEAM: Debt-to-Equity (D/E) ratio 0.24 (conservative), Current ratio is 13.09 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✓
MOAT Pass
70/100
BEAM: Gross margin is 84% (+21.1 pp trend), $3B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 70/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
73/100
Analyst outlook: 18 / 27 analysts rate BEAM as buy (67%). Analyst consensus target is $41 (+35.3% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
BEAM: Net profit margin is -57.2%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range13.525-36.44
Volume2.19M
Avg Volume (30D)2.1M
Market Cap$3.09B
Beta (1Y)2.19
Share Statistics
EPS (TTM)-0.81
Shares Outstanding$98.91M
IPO Date2020-02-06
Employees393
CEOJohn Evans
Financial Highlights & Ratios
Revenue (TTM)$139.74M
Gross Profit$117.45M
EBITDA$-29.92M
Net Income$-79.99M
Operating Income$-383.69M
Total Cash$1.25B
Total Debt$293.88M
Net Debt$-1.06M
Total Assets$1.48B
Price / Earnings (P/E)-37.4
Price / Sales (P/S)22.09
Analyst Forecast
1Y Price Target$41.00
Target High$74.00
Target Low$26.00
Upside+35.3%
Rating ConsensusBuy
Analysts Covering27
Buy 67% Hold 30% Sell 4%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS07373V1052

Price Chart

Track all markets on TradingView
BEAM
Beam Therapeutics Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
13.53 52WK RANGE 36.44

People Also View

VRTX
VRTX
Vertex Pharmaceuticals Incorporated
$444.28
+0.96%
 CRSP
CRSP
CRISPR Therapeutics AG
$56.86
+3.70%
 NTLA
NTLA
Intellia Therapeutics, Inc.
$14.78
+3.65%
 VERV
VERV
Verve Therapeutics, Inc.
$11.13
+0.27%
 SANA
SANA
Sana Biotechnology, Inc.
$3.48
+8.41%
 PRME
PRME
Prime Medicine, Inc.
$3.70
+1.09%
 DNA
DNA
Ginkgo Bioworks Holdings, Inc.
$7.72
+15.57%
 EDIT
EDIT
Editas Medicine, Inc.
$3.39
+5.94%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message